In a proof-of-concept study, a team of scientists in Spain has identified a range of blood markers related to immune responses that may help to track disease activity in people with IgG4-related disease (IgG4-RD). “In this prospective longitudinal study of [untreated] patients with IgG4-RD, [statistical] models identified exploratory associations…
News
Elevated blood levels of an antibody called IgG1, measured alongside a specific ratio to IgG4, can help identify a more severe form of IgG4-related disease (IgG4-RD) marked by widespread organ damage, a new study shows. Because the severity of IgG4-RD varies widely from person to person, researchers say evaluating…
People with IgG4-related disease (IgG4-RD) who have very high levels of the antibody immunoglobulin G4 (IgG4) are more likely to have multi-organ involvement, a study showed. The findings suggest that extremely high antibody levels — at or above five times the upper limit of normal (ULN) — might be…
The U.S. Food and Drug Administration (FDA) is now slated to decide by next year whether or not to approve the novel injection therapy obexelimab for immunoglobulin G4-related disease (IgG4-RD). The regulatory agency has accepted a biologics license application (BLA) from Zenas Biopharma, the therapy’s developer,…
A new scoring system that standardizes how tissue samples are evaluated under a microscope for IgG4-related disease (IgG4-RD) may help doctors diagnose the body-wide, immune-mediated disease more accurately and consistently, a study suggested. The system assigns numerical scores to multiple microscopic features in patients’ tissue samples, providing a “standardized,…
IgG4-related disease (IgG4-RD) can in some cases affect the voice box, causing symptoms such as voice changes and difficulty breathing. These cases can also be difficult to diagnose and treat, a review study highlights. Noting that this rare manifestation of IgG4-RD is likely to go unrecognized, the researchers emphasized…
In a proof-of-concept clinical trial, the oral treatment candidate zanubrutinib was shown to reduce disease activity for 10 people with hard-to-treat immunoglobulin G4-related disease (IgG4-RD) affecting the tear and salivary glands. Importantly, according to the researchers, zanubrutinib showed disease-controlling potential as a standalone therapy, bypassing the need for…
Valerio Therapeutics is teaming up with Abivax to discover new treatments for immune-mediated inflammatory diseases. The deal will provide funding to help advance Valerio’s internal pipeline, including a cell therapy candidate for IgG4‑related disease (IgG4‑RD), an immune-mediated inflammatory disease. “This collaboration brings together two highly complementary scientific…
A Phase 2 clinical trial Spero Therapeutics plans to start next year will test an investigational antibody-based therapy in people with immunoglobulin G4-related disease (IgG4-RD). Spero recently signed an exclusive license agreement with Innovent Biologics, the treatment’s original developer, that grants the company worldwide exclusive rights to develop, produce, and…
Cleveland Clinic specialists across multiple disciplines are working to speed the diagnosis of immunoglobulin G4-related disease (IgG4-RD), a rare and often-missed inflammatory condition. Their efforts include using artificial intelligence (AI) to develop a tool to help assess and manage the disease and create a patient registry. The specialists —…
